HeartBeam Inc. (NASDAQ: BEAT) has scheduled a conference call for Thursday, Nov. 12, 2026, at 4:30 p.m. ET to discuss its financial results for the third quarter ended Sept. 30, 2026. The call will be hosted by Executive Chairman Richard Ferrari, President and Founder Branislav Vajdic, Ph.D., and Chief Financial Officer Timothy Cruickshank, and will include a question-and-answer session. A press release detailing the quarterly results will be issued before the call.
The significance of the announcement extends beyond routine quarterly reporting. Management plans to provide updates on recent achievements, including results from the ALIGN-ACS pilot study, and upcoming milestones for the company’s Heart Attack Detection program. For investors and industry observers, these updates could offer critical insight into the clinical and regulatory progress of HeartBeam’s 3D ECG technology, which aims to transform cardiac care by enabling portable, cable-free ECG collection outside traditional medical facilities.
HeartBeam’s platform is designed to collect ECG signals in three non-coplanar directions and synthesize them into a 12-lead ECG, delivering actionable heart intelligence wherever the patient is. The company’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and for its 12-lead ECG synthesis software in December 2025. HeartBeam holds over 20 issued patents related to technology enablement. The ALIGN-ACS pilot study and the Heart Attack Detection program are central to the company’s efforts to expand the clinical utility of its platform, and updates on these fronts may signal how quickly the technology could move toward broader adoption.
Participants can access the conference by dialing 1-877-704-4453 domestically or 1-201-389-0920 internationally using conference code 13763268. A webcast and accompanying presentation will be available, with a telephone replay accessible approximately three hours after the call through Nov. 26, 2026. To view the full press release, visit https://ibn.fm/QEwx4.
For a deeper look at HeartBeam, refer to the company’s relationship page at HeartBeam (NASDAQ: BEAT). The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT. Details on the intended use of its technology can be found in the Company’s Cleared Indications for Use at https://www.heartbeam.com/indications.
The call comes as HeartBeam seeks to redefine cardiac health management by enabling physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility. With FDA clearances secured and a growing patent portfolio, the company’s ability to execute on its Heart Attack Detection program and translate pilot study results into clinical and commercial milestones will be closely watched. The third quarter call thus represents more than a financial update; it is an opportunity for management to outline how near-term data and regulatory steps could shape the company’s trajectory in the competitive cardiac monitoring space.
MissionIR, which distributes the announcement, operates as part of the Dynamic Brand Portfolio @ IBN and provides services including InvestorWire wire solutions, editorial syndication to 5,000+ outlets and social media distribution. These channels help amplify corporate announcements such as HeartBeam’s conference call notice, ensuring they reach a broad audience of investors and industry stakeholders.
